Update on Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Diagnosis and Management

2024-9-15

A Practice Approach to Acne Fulminans in Adolescents

2024-9-13

Image-Based Artificial Intelligence in Psoriasis Assessment: The Beginning of a New Diagnostic Era?

2024-9-11

Predictors and Management of Inadequate Response to JAK Inhibitors in Alopecia Areata

2024-9-3

Advances in the Application of Noninvasive Skin Imaging Techniques in Acne Scars

2024-8-12

Association of Cardiovascular Disease and Chronic Spontaneous Urticaria: A Case–Control Study

2024-8-5

Dapsone Use in Dermatology

2024-7-30

Hidradenitis Suppurativa: New Targets and Emerging Treatments

2024-7-26

Sequencing of Targeted Therapy in Psoriasis: Does it Matter?

2024-7-13

Lichen Planus: What is New in Diagnosis and Treatment?

2024-7-9

Clinical Efficacy and Safety of Interleukin-17 Inhibitors in Treating Patients with Erythrodermic Psoriasis: A Retrospective Cohort, Three-Center Study

2024-7-5

Efficacy and Safety of Brodalumab, an Anti-interleukin-17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16-Week Results of a Randomized Clinical Trial

2024-7-2

Human Inborn Errors of Immunity in Pyoderma Gangrenosum: A Systematic Review

2024-7-1

Association Between Biologic Exposure and the Risk of Depression in Patients with Psoriasis: A Retrospective Analysis of Large US Administrative Claims Data

2024-6-27

The Current State of Systemic Therapy of Metastatic Uveal Melanoma

2024-6-22

An Update on New and Existing Treatments for the Management of Melasma

2024-6-19

Evaluation of the Tolerability of Hedgehog Pathway Inhibitors in the Treatment of Advanced Basal Cell Carcinoma: A Narrative Review of Treatment Strategies

2024-6-19

Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure

2024-6-18

Adherence to Hidradenitis Suppurativa Treatment

2024-6-11

Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis Treatment

2024-5-27

Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

2024-5-24

The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases

2024-5-20

Management and Long-Term Outcomes of Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS) in Children: A Scoping Review

2024-5-16

Managing the Patient with Psoriasis and Metabolic Comorbidities

2024-5-15

Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study

2024-5-14

Approach to the Atypical Wound

2024-5-14

Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies

2024-5-2

American Academy of Dermatology Annual Meeting: San Diego, CA, USA, 8–12 March 2024

2024-4-26

Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates

2024-4-22

Ultrasound Surveillance in Melanoma Management: Bridging Diagnostic Promise with Real-World Adherence: A Systematic Review and Meta-Analysis

2024-4-18

Secondary Bacterial Infections in Patients with Atopic Dermatitis or Other Common Dermatoses

2024-4-5

Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)

2024-3-25

Tree-Based Machine Learning to Identify Predictors of Psoriasis Incidence at the Neighborhood Level: A Populational Study from Quebec, Canada

2024-3-18

Expert Panel Review of Skin and Hair Dermatophytoses in an Era of Antifungal Resistance

2024-3-18

Management of Acne in Pregnancy

2024-3-7

Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis

2024-3-4

Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma

2024-2-26

The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature

2024-2-16

Field Cancerization Therapies for the Management of Actinic Keratosis: An Updated Review

2024-2-13

Correction to: OX40 in the Pathogenesis of Atopic Dermatitis—A New Therapeutic Target

2024-2-10

Autoimmune, Autoinflammatory Disease and Cutaneous Malignancy Associations with Hidradenitis Suppurativa: A Cross-Sectional Study

2024-2-9

Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma

2024-2-8

Autoimmune and Cutaneous Inflammatory Comorbidities in Adult-Onset Morphea in the All of Us Research Program

2024-2-2

Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study

2024-1-24

Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

2024-1-23

The Skin Microbiome and its Significance for Dermatologists

2024-1-22

Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year

2024-1-19

OX40 in the Pathogenesis of Atopic Dermatitis—A New Therapeutic Target

2024-1-18

Mucocutaneous Manifestations of Recreational Drug Use

2024-1-13

Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors

2024-1-12